Protagonist Therapeutics Inc (PTGX)

NASDAQ
39.64
+5.80(+17.14%)
After Hours
39.90
+0.26(+0.66%)
- Real-time Data
  • Volume:
    864,395
  • Bid/Ask:
    38.20/43.37
  • Day's Range:
    33.58 - 40.46

PTGX Overview

Prev. Close
33.84
Day's Range
33.58-40.46
Revenue
31.17M
Open
33.73
52 wk Range
14.16-40.46
EPS
-1.82
Volume
864,395
Market Cap
1.74B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
320,366
P/E Ratio
-
Beta
1.54
1-Year Change
144.99%
Shares Outstanding
43,945,166
Next Earnings Date
Aug 10, 2021
What is your sentiment on Protagonist Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Protagonist Therapeutics Inc News

Protagonist Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Protagonist Therapeutics Inc Company Profile

Protagonist Therapeutics Inc Company Profile

Employees
83

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.